PRIVATE clinical-stage
biotherapeutics company, Jennerex,
has entered into a partnership with
bio-pharmaceutical company
Transgene to develop and
commercialise JX-594 for the
treatment of solid tumors in
Europe, the Commonwealth and
the Middle East.
JX-594 is Jennerex’s lead cancer
biotherapeutic product, and has
shown anticancer activity and a
well tolerated safety profile in Phase
1 and Phase 2 clinical trials to date.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.